Jak2 inhibition deactivates Lyn kinase through the SET–PP2A–SHP1 pathway, causing apoptosis in drug-resistant cells from chronic myelogenous leukemia patients

Chronic myelogenous leukemia (CML) patients treated with imatinib mesylate (IM) become drug resistant by mutations within the kinase domain of Bcr–Abl, and by other changes that cause progression to advanced stage (blast crisis) and increased expression of the Lyn tyrosine kinase, the regulation of...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Samanta, AK, Chakraborty, SN, Wang, Y, Kantarjian, H, Sun, X, Hood, J, Perrotti, D, Arlinghaus, RB
Formato: Artigo
Idioma:Inglês
Publicado em: 2009
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2841483/
https://ncbi.nlm.nih.gov/pubmed/19234487
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/onc.2009.7
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados